Vedolizumab has no efficacy on articular manifestations in patients with spondyloarthritis associated with inflammatory bowel disease

Rubin, 2016, The effect of vedolizumab on extraintestinal manifestations in patients with Crohn's disease in GEMINI 2, Inflamm Bowel Dis, 22, 105, 10.1097/01.MIB.0000480260.28955.65

Tadbiri, 2018, GETAID OBSERV-IBD study group. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort., Aliment Pharmacol Ther, 47, 485, 10.1111/apt.14419

Varkas, 2017, An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series, Ann Rheum Dis, 76, 878, 10.1136/annrheumdis-2016-210233

Wendling, 2018, Arthritis occurrence or reactivation under Vedolizumab treatment for inflammatory bowel disease. A four cases report, Jt Bone Spine, 85, 255, 10.1016/j.jbspin.2017.01.012

Dubash, 2018, Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease, Rheumatology (Oxford)

Orlando, 2017, Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease, Ann Rheum Dis, 76, 31, 10.1136/annrheumdis-2016-211011